Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries.
about
Epithelial-derived TGF-beta2 modulates basal and wound-healing subepithelial matrix homeostasisLocalized ultrasound enhances delivery of rapamycin from microbubbles to prevent smooth muscle proliferation.Sirolimus inhibits key events of restenosis in vitro/ex vivo: evaluation of the clinical relevance of the data by SI/MPL- and SI/DES-ratiosRapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells.Concentration-dependent differential effects of udenafil on viability, proliferation, and apoptosis in vascular endothelial and smooth muscle cells.Targeting PI3Kγ activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response.Paclitaxel induces thrombomodulin downregulation in human aortic endothelial cells.Sirolimus-eluting dextran and polyglutamic acid hybrid coatings on AZ31 for stent applications.Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activationPromoting vascular regeneration as an alternative to conventional angioplasty-based intervention.Induction of vascular atrophy as a novel approach to treating restenosis. A reviewRapamycin attenuates endothelial apoptosis induced by low shear stress via mTOR and sestrin1 related redox regulation.Paclitaxel drug delivery systems.Unprotected distal left main bifurcation drug eluting stent restenosis: first successful experience with simultaneous kissing balloon dilatation using sirolimus coated balloon.The integrin ligand c(RGDf(NMe)Nal) reduces neointimal hyperplasia in a polymer-free drug-eluting stent system.Resistance to fas-induced apoptosis in cells from human atherosclerotic lesions: elevated Bcl-XL inhibits apoptosis and caspase activation.Rapamycin induces transactivation of the EGFR and increases cell survival.In vivo comparison of a polymer-free Biolimus A9-eluting stent with a biodegradable polymer-based Biolimus A9 eluting stent and a bare metal stent in balloon denuded and radiated hypercholesterolemic rabbit iliac arteries.MicroRNA-21 mediates the rapamycin-induced suppression of endothelial proliferation and migration.In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function.In vitro study of dual drug-eluting stents with locally focused sirolimus and atorvastatin release.Effects of Tacrolimus or Sirolimus on the adhesion of vascular wall cells: Controlled in-vitro comparison study.Ibuprofen inhibits migration and proliferation of human coronary artery smooth muscle cells by inducing a differentiated phenotype: role of peroxisome proliferator-activated receptor γ.Drug-Eluting Stent Design is a Determinant of Drug Concentration at the Endothelial Cell Surface.Preparation and experimental research into retrievable rapamycin- and heparin-coated vena cava filters: a pilot study.Pharmacokinetic Evaluation of Two Paclitaxel-Coated Balloons with Different Drug Load in a Short-Term Porcine Study.Decorin mimic promotes endothelial cell health in endothelial monolayers and endothelial-smooth muscle co-cultures.Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease
P2860
Q24299083-E93132FA-C311-4327-85A8-CC1FF8208AABQ30425418-4419739C-704C-408B-9EA9-E2EB36531005Q31112412-A762036A-C363-4CA1-A85D-BF1844DC66DAQ33776274-1248F194-2500-410A-834F-2C203A9B30D0Q33809405-EE2227B1-5C68-4D82-95A1-60D9AAD426B9Q34089207-AECD2622-46B9-42DD-8249-B405512225BFQ34698151-6C00571E-71B3-4846-A593-23A73ADF750BQ35707420-F70FB06F-0ECC-4286-B372-59475EF73A2FQ35820068-EA716A39-5435-4DDF-94B7-B403894FA5E9Q36684479-00603996-B5B4-4022-9E5F-BDC31D9CDD0BQ36976632-2D76E2B1-41EF-42C0-A388-665972AD4873Q37577274-EA5684C0-97DD-4852-8E38-B452553ADA57Q38071668-21ED0907-E9A9-44C5-A07E-1E77CFB0880AQ38253729-9D3121E0-B374-4CE3-A618-F3745B62BF00Q39007117-8842DD1E-9200-49D9-B005-D01351EAC122Q40101793-BC991088-7C78-4541-98E0-D8CD4AD2DBECQ41951665-82F8EC68-895C-4303-97B3-234DEC62E9D8Q44067567-E9D8E939-C76B-44CD-9F7E-23D778014B27Q45330530-B99D6E55-E9D7-42BA-8895-A0FCDB2F813DQ46771769-39E97EE0-C2E8-489A-8DA4-D25BFA787628Q46783365-2C3E1146-1801-49B3-B0CF-538CB9890DAFQ50225555-C3D3D8C7-92CF-4A2A-B494-3B42AF54AE77Q50226170-E049A9A6-4853-4A13-9908-EC516F247AC6Q51543484-F76023EC-9509-4EBC-9D8B-42E38240EFBAQ51722034-D69874ED-DA2F-4F83-884B-9556A7C68615Q53118939-68D3A99E-E65A-4169-AFB3-902EAE0136C1Q53219522-E835B273-053B-49BD-AAB9-0356BB7F42EEQ56384060-2215864A-A621-4509-86D3-20FE1A97CD51
P2860
Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Drug-eluting stents: sirolimus ...... ed cells and injured arteries.
@en
Drug-eluting stents: sirolimus ...... ed cells and injured arteries.
@nl
type
label
Drug-eluting stents: sirolimus ...... ed cells and injured arteries.
@en
Drug-eluting stents: sirolimus ...... ed cells and injured arteries.
@nl
prefLabel
Drug-eluting stents: sirolimus ...... ed cells and injured arteries.
@en
Drug-eluting stents: sirolimus ...... ed cells and injured arteries.
@nl
P2093
P1476
Drug-eluting stents: sirolimus ...... ed cells and injured arteries.
@en
P2093
Demetrius Carter
Dennis Argentieri
John Siekierka
Rathna Thyagarajan
Robert Falotico
Ruth Brosius
Tom J Parry
P356
10.1016/J.EJPHAR.2005.09.042
P407
P577
2005-11-03T00:00:00Z